Showing results (1311-1320 of 2,357) with videos related to
Sort By:
Pageof 236
Clinical Neuropharmacology|February 1, 1997
The management of coexisting depression in patients with dementia: potential of calcium channel antagonistsJ De Vry, J Fritze, R M PostClinical Neuropharmacology|February 1, 1997
Acute risperidone overdoseG Catalano, M C Catalano, W TaylorClinical Neuropharmacology|April 1, 1997
Minimal rebound insomnia after treatment with 10-mg zolpidemJ C Ware, J K Walsh, M B Scharf, et al.Clinical Neuropharmacology|April 1, 1997
Emergence of kleptomania during treatment for depression with serotonin selective reuptake inhibitorsS Kindler, P N Dannon, I Iancu, et al.Clinical Neuropharmacology|April 1, 1997
Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study GroupJ Ghika, J P Gachoud, U GasserClinical Neuropharmacology|April 1, 1997
Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose studyM Merello, R Pikielny, A Cammarota, et al.Clinical Neuropharmacology|April 1, 1997
Spiking fevers with clozapine treatmentF Trémeau, S C Clark, D Printz, et al.Clinical Neuropharmacology|October 1, 1996
The study of neurotransmitter interactions using positron emission tomography and functional couplingR Schloesser, P Simkowitz, E J Bartlett, et al.Clinical Neuropharmacology|October 1, 1996
pros-Methylimidazoleacetic acid in cerebrospinal fluid of patients with chronic schizophrenia: relationships to ratings of symptoms, ventricular brain ratios, and rates of urine excretionG D Prell, J P Green, J K Khandelwal, et al.Clinical Neuropharmacology|October 1, 1996
A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patientsM E Llau, G Durrieu, M A Tran, et al.Pageof 236